Cardio Diagnostics Holdings (NASDAQ: CDIO) took center stage in the latest episode of The BioMedWire Podcast, where CEO and Co-Founder Dr. Meesha Dogan detailed the company's mission to revolutionize cardiovascular disease prevention and early detection through precision medicine powered by epigenetics, genetics, and artificial intelligence.
During the interview, Dogan emphasized the significance of Cardio Diagnostics' proprietary AI-driven Integrated Genetic-Epigenetic Engine, which enables more personalized and precise cardiovascular care. She noted that the company's tests are designed to make prevention, detection, and management of cardiovascular disease more accessible to a broader population.
A key highlight of the discussion was Cardio Diagnostics' expansion into India, facilitated through partnerships with Aimil Ltd. and Dr. Lal PathLabs. This move aims to address the growing burden of cardiovascular disease in one of the world's most populous countries, leveraging the company's innovative technology to improve outcomes on a global scale.
Dogan also provided an update on the company's progress through the Medicare reimbursement process. She confirmed that the CPT coding and payment steps have been completed, a critical milestone for ensuring that Cardio Diagnostics' tests are covered by Medicare. However, the coverage determination remains underway, which will ultimately decide the extent of reimbursement for the tests.
The company's forward-looking statements, as outlined in its SEC filings, caution that actual results may differ materially due to various risks and uncertainties. Cardio Diagnostics encourages investors to review the risk factors detailed in its most recent Annual Report on Form 10-K and subsequent filings with the SEC.
For more information on Cardio Diagnostics and its latest developments, visit the company's newsroom at https://ibn.fm/CDIO.
